Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Xenon ( (XENE) ) is now available.
On November 24, 2025, Xenon Pharmaceuticals Inc. amended its 2025 Inducement Equity Incentive Plan to increase the number of shares reserved for issuance from 775,000 to 900,000. This adjustment is intended to facilitate the granting of various stock-related incentives to new or returning employees without requiring shareholder approval, in line with Nasdaq Listing Rule 5635(c)(4).
The most recent analyst rating on (XENE) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
Xenon’s primary strengths lie in its strong financial position and positive clinical development progress, as highlighted in the earnings call. However, the absence of revenue and profitability, along with technical and valuation concerns, weigh heavily on the overall stock score.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Average Trading Volume: 776,152
Technical Sentiment Signal: Buy
Current Market Cap: $3.46B
See more insights into XENE stock on TipRanks’ Stock Analysis page.